Blood Plasma Derivatives Market Statistics
The global blood plasma derivatives market is projected to observe a remarkable growth at a CAGR of 9.5% between 2020 to 2030. The market was valued USD 36. 47 bn and might reach the anticipated value of USD 89.76 bn
The increasing incidences of life-threatening diseases such as monoclonal immunoglobulin are expected to drive the plasma derivatives market primarily.
Hepatitis B to Drive the Blood Plasma Derivatives Market
Plasma derivatives are classified into two categories, low and high risk of transmitting hepatitis. Hepatitis B is a serious health problem that occurs worldwide. Hepatitis B causes serious damages to liver and the plasma derivatives is expected to help in the treatment, thus providing the growth opportunities for the global blood plasma derivatives market.
Hepatitis B when gets identified can also prevent the viral hepatitis with the help of plasma derivatives, owing to the boost in the demand for blood plasma derivatives.
Haemophilia to Strengthen Blood Plasma Derivatives Market
Haemophilia is a rare disease occurs due to genetic factors and so far, there is no cure for this disorder. The treatment line for this disease includes administering blood plasma into the patients, the process includes mandatory screening to inactivate the viruses received from blood donors. This new change in the blood plasma donations have totally changed the dynamics of treatment, unlike the earlier process where the blood plasma was collected from various donors and given to the patients. This new method of stringent screening has minimized the risk of contamination of plasma derivatives, owing to the expansion of the global blood plasma derivatives market in the coming years.
However, high cost of treatment is expected to hamper the growth of the global blood plasma derivatives market during the forecast period.
Nonetheless, the research and development in the field of finding treatment for various diseases is anticipated to drive the global blood plasma derivatives market in the forthcoming years.
| Data Points | Market Insights |
| Market Value 2020 | US$ 36.47billion |
| Market Value 2030 | US$ 89.76billion |
| Market Growth Rate 2020-2030 | 9.5% |
| Top Regional Market | North America |
| Key Players | Grifols, S.A., Baxter International Inc., CSL Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Bain Capital, LLC and Biotest AG. |
| Segment | Product Outlook, Form Outlook, Applications Outlook |
Immunoglobulin Segment to Boost the Demand for Blood Plasma Derivatives
On the basis of type, the global blood plasma derivatives market is segmented into – albumin, immunoglobulin, Factor VIII, Factor IX, Hyperimmune Globin, and Others. However, the immunoglobulin segment is expected to dominate during the forecast period.
Plasma derived immunoglobulin plays a key role in humoral immunity and five isotypes are found in human blood plasma along with the effector function which further ensures protection from infections. The IgG isotype is the commonly turned into pharmaceutical product that can be used to treat immunodeficiency disorders.
On the other hand, albumin segment is anticipated considerably grow due to growing demand for albumin products.
On the basis of applications, the global haemophilia, immunodeficiency diseases, hypogammaglobulinemia, Von Willebrand’s disease, and other applications. However, during the forecast years, the others applications is expected to hold a highest share in the market. The growth of other applications can be attributed to rising demand for plasma derived products and growing prevalence of infectious disease.
Alongside, the immunodeficiency is projected to grow at a substantial rate, owing to the rising incidences of immune diseases.
On the basis of end users, the global blood plasma derivatives are segmented into- hospitals and clinics. However, hospital segment is likely to dominate the global blood plasma derivatives market due to increasing cases of immune deficiency and infectious diseases.
Regional Outlook
On the basis of region, North America is expected to lead the global blood plasma derivatives market over the forecast years. The growth in the region can be primarily due to the presence of key players and approved plasma derivatives products.
Simultaneously, Asia Pacific is likely to witness a considerable growth during the forecast period. The growth in the region could be due to growing healthcare facilities and awareness about plasma derivative products.
Competitive Landscape
In April 2022, Baxter International Inc., a world leader in healthcare announced about the Food and Drug and Administration’s approval of ST set that is used in Continuous Renal Replacement Therapy. The set is already connected, disposable, and extracorporeal, and is made available in the U.S to meet the diverse demands of patients that are treated with CRTT.
In April 2022, Grifols, a world leader in plasma derived medicines announced the 100 % acquisition of Tiancheng Pharmaceutical Holdings. The acquisition will strengthen the plasma derived therapies and to accelerate growth and innovation in the healthcare sector.
In Jan 2022, Fusion Pharmaceuticals announced collaboration with Pepscan to report and develop next generation peptides radiopharmaceuticals as precision medicines.
The key players of the global blood plasma derivatives market-
- Kedrion S.p.A
- LFB S.A.
- Bain Capital
- LLC and Biotest AG.
- Grifols, S.A.
- Baxter International Inc.
- CSL Limited
- Octapharma AG
By Type
- Intravenous immunoglobulin (IVIG)
- Fresh Frozen Plasma (FFP)
- Albumin
- Factor VIII
- Factor IX
By Application
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia Pacific
- China
- India
- Japan
- South Korea
Latin America
- Brazil
- Mexico
Middle East & Africa (MEA)
Frequently Asked Questions
What is the growth rate of blood plasma derivatives market?
The global blood plasma derivatives market is expected to grow at a CAGR of 9.5%
What are the opportunities in the global blood plasma derivatives market?
The market for blood plasma derivatives is driven by geriatric population, more in developed countries, leading to growth opportunities.
What are the challenges in the blood plasma derivatives market?
Stringent government regulations pertaining to product quality and safety act as major restraints for the market growth.
What the major factors that derive the global blood plasma derivatives market?
The market is driven by factors such as increasing prevalence of vascular and cardiovascular diseases.
Table Of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By By Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By By Type, 2022-2032
5.3.1. Intravenous immunoglobulin (IVIG)
5.3.2. Fresh Frozen Plasma (FFP)
5.3.3. Albumin
5.3.4. Factor VIII
5.3.5. Factor IX
5.4. Y-o-Y Growth Trend Analysis By By Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By By Type, 2022-2032
6. Global Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By By Application, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By By Application, 2022-2032
6.3.1. Hemophilia A
6.3.2. Hemophilia B
6.3.3. Von Willebrand Disease
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By By Application, 2017-2021
6.5. Absolute $ Opportunity Analysis By By Application, 2022-2032
7. Global Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By By Type
8.2.3. By By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By By Type
8.3.3. By By Application
8.4. Key Takeaways
9. Latin America Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Chile
9.2.1.5. Peru
9.2.1.6. Rest of Latin America
9.2.2. By By Type
9.2.3. By By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By By Type
9.3.3. By By Application
9.4. Key Takeaways
10. Europe Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By By Type
10.2.3. By By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By By Type
10.3.3. By By Application
10.4. Key Takeaways
11. East Asia Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By By Type
11.2.3. By By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By By Type
11.3.3. By By Application
11.4. Key Takeaways
12. South Asia Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By By Type
12.2.3. By By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By By Type
12.3.3. By By Application
12.4. Key Takeaways
13. Oceania Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By By Type
13.2.3. By By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By By Type
13.3.3. By By Application
13.4. Key Takeaways
14. MEA Blood Plasma Derivatives Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By By Type
14.2.3. By By Application
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By By Type
14.3.3. By By Application
14.4. Key Takeaways
15. Key Countries Blood Plasma Derivatives Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By By Type
15.1.2.2. By By Application
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By By Type
15.2.2.2. By By Application
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By By Type
15.3.2.2. By By Application
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By By Type
15.4.2.2. By By Application
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By By Type
15.5.2.2. By By Application
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. Â By Regional
16.3.2. Â By By Type
16.3.3. Â By By Application
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Kedrion S.p.A
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. LFB S.A.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Bain Capital
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. LLC and Biotest AG.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Grifols, S.A.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Baxter International Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. CSL Limited
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Octapharma AG
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Request Free Sample
